Market research
CSL.AU CSL Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 80B
- P/E ratio
- Not available
- Analyst target
- 171.8091
- Dividend yield
- 1.7%
- Beta
- 0.12
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU000000CSL8
- Market cap
- 80B
- P/E ratio
- Not available
- Analyst target
- 171.8091
- Dividend yield
- 1.7%
- Beta
- 0.12
About
About CSL Limited
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. The company's therapeutic areas includes Immunoglobulins, Immunology, Immunology Haematology, Cardiovascular and Renal, and Vaccines. It also licenses CSL intellectual property. It also develops vaccines for the prevention of infectious disease. The company has strategic collaboration with Dutch biotech company VarmX BV for the development of VMX-C001 to help restore blood coagulation in patients requiring urgent surgery. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CSL.AU discussion.
5 years, 5 months ago
CSL Limited is currently in a long term downtrend where the price is trading 1.1% below its 200 day moving average.
From a valuation standpoint, the stock is 96.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.7.
CSL Limited's total revenue rose by 16.9% to $6B since the same quarter in the previous year.
Its net income has increased by 45.0% to $2B since the same quarter in the previous year.
Finally, its free cash flow grew by 1176.5% to $878M since the same quarter in the previous year.
Based on the above factors, CSL Limited gets an overall score of 4/5.